Moderna (NASDAQ:MRNA) announced on Saturday that the U.S. Food and Drug Administration (FDA) approved its next-gen COVID-19 vaccine, mNEXSPIKE (mRNA-1283), making it the Cambridge, Massachusetts-based biotech’s third FDA-approved product.

Accordingly, mNEXSPIKE will be indicated in the U.S. for adults aged 65 and